NAVB - Navidea Biopharmaceuticals, Inc

NYSE American - NYSE American Delayed Price. Currency in USD
0.291
-0.008 (-2.838%)
At close: 3:55PM EDT
Stock chart is not supported by your current browser
Previous Close0.299
Open0.300
Bid0.000 x 0
Ask0.000 x 0
Day's Range0.290 - 0.305
52 Week Range0.290 - 0.680
Volume176,037
Avg. Volume293,288
Market Cap47.159M
Beta-1.19
PE Ratio (TTM)0.63
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEventslast month

    Edited Transcript of NAVB earnings conference call or presentation 8-Mar-18 9:30pm GMT

    Q4 2017 Navidea Biopharmaceuticals Inc Earnings Call

  • Associated Presslast month

    Navidea reports 4Q loss

    The Dublin, Ohio-based company said it had a loss of 3 cents per share. The biopharmaceutical posted revenue of $395,100 in the period. Its adjusted revenue was $395,000. For the year, the company reported ...

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of NAVB earnings conference call or presentation 8-Nov-17 1:30pm GMT

    Q3 2017 Navidea Biopharmaceuticals Inc Earnings Call

  • Associated Press5 months ago

    Navidea reports 3Q loss

    On a per-share basis, the Dublin, Ohio-based company said it had a loss of 1 cent. The biopharmaceutical posted revenue of $223,700 in the period. Its adjusted revenue was $224,000. In the final minutes ...

  • SmarterAnalyst6 months ago

    Why Shares of Navidea Biopharmaceuticals Inc (NAVB) Are Surging 25%

    It’s been a good day for shareholders of tiny-size biotech company Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB). Shares of Navidea spiked sharply Friday after the company announced the execution of a non-binding letter of intent with CerveauTechnologies sub-licensing the worldwide rights to conduct research using NAV4694, a beta-amyloid imaging agent being evaluated as an aid in the differential diagnosis of early-onset Alzheimer’s disease, as well as an exclusive license for the development and commercialization of NAV4694 in Australia, Canada, China, and Singapore. NAVB has a 1-year high of $1.16 and a 1-year low of $0.29.

  • Capital Cube7 months ago

    ETFs with exposure to Navidea Biopharmaceuticals, Inc. : September 28, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Navidea Biopharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to NAVB-US. Comparing the performance and risk of Navidea Biopharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Navidea Biopharmaceuticals, Inc. :NAVB-US: Earnings Analysis: Q2, 2017 By the Numbers : September 27, 2017
    Capital Cube7 months ago

    Navidea Biopharmaceuticals, Inc. :NAVB-US: Earnings Analysis: Q2, 2017 By the Numbers : September 27, 2017

    Categories: Yahoo FinanceGet free summary analysis Navidea Biopharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Navidea Biopharmaceuticals, Inc. – Immunomedics, Inc., AMAG Pharmaceuticals, Inc., Cardinal Health, Inc., International Isotopes Inc., Fonar Corporation, iCAD, Inc. and Austal Limited Sponsored ADR (IMMU-US, AMAG-US, CAH-US, INIS-US, ... Read more (Read more...)

  • Thomson Reuters StreetEvents8 months ago

    Edited Transcript of NAVB earnings conference call or presentation 9-Aug-17 12:00pm GMT

    Q2 2017 Navidea Biopharmaceuticals Inc Earnings Call

  • Associated Press8 months ago

    Navidea reports 2Q loss

    On a per-share basis, the Dublin, Ohio-based company said it had a loss of 3 cents. Losses, adjusted to account for discontinued operations, were 2 cents per share. The biopharmaceutical posted revenue ...

  • Capital Cube10 months ago

    ETFs with exposure to Navidea Biopharmaceuticals, Inc. : June 9, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Navidea Biopharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to NAVB-US. Comparing the performance and risk of Navidea Biopharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Navidea Biopharmaceuticals, Inc. :NAVB-US: Earnings Analysis: Q1, 2017 By the Numbers : May 26, 2017
    Capital Cube11 months ago

    Navidea Biopharmaceuticals, Inc. :NAVB-US: Earnings Analysis: Q1, 2017 By the Numbers : May 26, 2017

    Categories: Yahoo FinanceGet free summary analysis Navidea Biopharmaceuticals, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Navidea Biopharmaceuticals, Inc. – Immunomedics, Inc., AMAG Pharmaceuticals, Inc., Eli Lilly and Company, General Electric Company, Cardinal Health, Inc., International Isotopes Inc., Fonar Corporation and iCAD, Inc. (IMMU-US, ... Read more (Read more...)

  • Thomson Reuters StreetEvents11 months ago

    Edited Transcript of NAVB earnings conference call or presentation 10-May-17 12:00pm GMT

    Q1 2017 Navidea Biopharmaceuticals Inc Earnings Call

  • Associated Press11 months ago

    Navidea posts 1Q profit

    The Dublin, Ohio-based company said it had profit of 52 cents per share. Losses, adjusted to account for discontinued operations, came to 1 cent per share. The biopharmaceutical posted revenue of $580,000 ...